Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 9/29/21 → 6/28/25 |
Funding
- IQVIA RDS Incorporated: $219,790.00
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naive Mantle Cell Lymphoma (BRUIN MCL-321)
- Munker, Reinhold (PI)